Atossa Therapeutics Inc (NASDAQ: ATOS) kicked off on Monday, up 8.00% from the previous trading day, before settling in for the closing price of $1.50. Over the past 52 weeks, ATOS has traded in a range of $0.62-$2.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 7.29%. With a float of $125.71 million, this company’s outstanding shares have now reached $125.76 million.
Let’s determine the extent of company efficiency that accounts for 12 employees. In terms of profitability, gross margin is -44.44%, operating margin of -169844.44%, and the pretax margin is -143944.44%.
Atossa Therapeutics Inc (ATOS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 21.22%. The most recent insider transaction that took place on Apr 10 ’24, was worth 44,250. In this transaction Director of this company bought 25,000 shares at a rate of $1.77, taking the stock ownership to the 25,000 shares. Before that another transaction happened on Nov 15 ’23, when Company’s Former EVP, CFO, & Director sold 50,000 for $0.65, making the entire transaction worth $32,500. This insider now owns 55 shares in total.
Atossa Therapeutics Inc (ATOS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.05 earnings per share (EPS), higher than consensus estimate (set at -0.07) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.29% per share during the next fiscal year.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Take a look at Atossa Therapeutics Inc’s (ATOS) current performance indicators. Last quarter, stock had a quick ratio of 14.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Looking closely at Atossa Therapeutics Inc (NASDAQ: ATOS), its last 5-days average volume was 0.75 million, which is a drop from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 94.62%. Additionally, its Average True Range was 0.07.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 93.75%, which indicates a significant increase from 87.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.19% in the past 14 days, which was lower than the 56.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4402, while its 200-day Moving Average is $1.3601. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $1.7000. Second resistance stands at $1.7800. The third major resistance level sits at $1.9000. If the price goes on to break the first support level at $1.5000, it is likely to go to the next support level at $1.3800. Now, if the price goes above the second support level, the third support stands at $1.3000.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
The company with the Market Capitalisation of 203.73 million has total of 125,757K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -30,090 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,050 K.
